September 12, 2016

Laura C. Bowman, M.D.

Curriculum Vitae, Laura C. Bowman, M.D.

ACADEMIC DEGREES

  • B.A. 1977 Indiana University, Bloomington, IN (Biology, Chemistry)
  • M.D. 1981 Indiana University School of Medicine, Indianapolis, IN

PROFESSIONAL APPOINTMENTS

  • 1981-84 Pediatric Residency, Medical University of South Carolina, Charleston, SC
  • 5/1/85- 6/30/85 Visiting Fellow, Fred Hutchison Cancer Research Center, Bone Marrow Transplantation Unit, Seattle, WA
  • 1984-87 Pediatric Fellow, Department of Hematology/Oncology, St. Jude Children’s Research Hospital, Memphis, TN
  • 1987-93 Assistant Member, Department of Hematology/Oncology, St. Jude Children’s Research Hospital, Memphis, TN
  • 1987-93 Assistant Professor, University of Tennessee, Memphis, Department of Pediatrics
  • 1993-01 Associate Member, Department of Hematology/Oncology, St. Jude Children’s Research Hospital, Memphis, TN
  • 1993-01 Associate Professor, University of Tennessee, Memphis, College of Medicine, Department of Pediatrics
  • 1997-01 Clinical Director, Division of Bone Marrow Transplant, St. Jude Children’s Research Hospital
  • 1998-01 Co-leader, Transplantation and Gene Therapy Program, St. Jude Children’s Research Hospital.
  • 7/2001-03 Director, Blood and Marrow Transplant, Children’s Healthcare of Atlanta at Egleston.

CERTIFICATION

  • American Academy of Pediatrics, June 1989
  • Board certified – American Board of Hematology/Oncology – July 1990, Re-certified May 1996, March 2009
  • Helms School for Medical Acupuncture, May 2010
  • American Academy of Medical Acupuncture, Board Certification May 2012

LICENSURE

  • MD Georgia #50471; Acupuncture Privileges 6/2010

RESEARCH INTERESTS

  • Integrative Oncology
  • Pediatric Acupuncture
  • Pain Management
  • Alternate Donor Allogeneic Bone Marrow Transplantation
  • Adoptive immunotherapy in pediatric malignancies
  • Cytokine modified tumor vaccines
  • High-dose chemotherapy with stem cell rescue for malignant solid tumors
  • Neuroblastoma therapy
  • Experimental therapeutics
  • Hepatic tumors

CLINICAL RESEARCH ACTIVITIES

EXTRAMURAL:

  • Full Member, Children’s Oncology Group (2000-present)
  • Full Member, Pediatric Oncology Group (1987-2000)
  • COG Neuroblastoma Committee (2000-present)
  • POG Neuroblastoma Core Committee (1988-2000)
  • COG Hepatoblastoma Committee (2000-present)
  • POG Hepatoblastoma Subcommitee (1989-Present), Chair (1997-Present)
  • Study Coordinator, POG 8743 (Jan. 1987 – Nov. 1990; 205 patients)
  • Treatment in “Better Risk” Neuroblastoma: POG Stage B (all ages) and POG Stage C, D, and DS < 365 days
  • Study Coordinator, POG 9243 (open 3/92; expected accrual – 200 patients)
  • Treatment for Children with Intermediate – Risk
  • Neuroblastoma: POG Stage (all ages) and POG Stages C, D, and DS (
  • Co-study Coordinator, POG 9345 (open 3/93, expected accrual – 60 patients)
  • Treatment of Unresectable/Metastatic Hepatoblastoma with Chemotherapy and Surgery: A Pediatric Oncology Group Pilot Study
  • Study Coordinator, POG 9645 Intergroup Protocol for Treatment of Children with Hepatoblastoma

St. Jude Principal Investigator:

  • POG 9645?Intergroup Protocol for Treatment of Children with Hepatoplastoma
  • POG 9345?Treatment of Unresectable/Metastatic Hepatoblastoma with Chemotherapy and Surgery: A Pediatric Oncology Group Pilot Study
  • POG 9243?Treatment for Children with Intermediate – Risk Neuroblastoma: POG Stage (all ages) and POG Stages C, D, and DS (
  • POG 9047 (open 3/31/92 – Present)?Neuroblastoma Biology Protocol
  • POG 8945 (open 9/19/89 – Present)?An Intergroup Protocol for the Treatment of Childhood Hepatoblastoma and Hepatocellular Carcinoma
  • POG 8441 (open 4/6/87 – close 3/22/88)?Therapy for Child with Stage D Neuroblastoma, Older than 365 Days at Diagnosis (Phase III) Single Patient Protocol
  • POG 8104/8105 (open 4/6/82 – close 10/16/90)?Therapy for Neuroblastoma

SJCRH INTRAMURAL:

  • Co, leader, Transplantation and Gene Therapy Program
  • Bone Marrow Transplantation Committee
  • Solid Tumor Committee
  • Neuroblastoma Subcommittee
  • Rhabdomyosarcoma Subcommittee
  • Head, Hepatic Tumor Subcommittee

Coinvestigator:

  • TOIT Treatment of Severe Osteogenesis Imperfecta BU ALLO BMT; 11/30/95-2000
  • DOLE Phase I administration of donor leukocytes to allo BMT recipients; 12/7/95-1999
  • ETNAWAS Administration of EBV specific cytotoxic T- lymphocytes in patients with Wiskott-Aldrich syndrome receiving a t-depleted bone marrow transplant; open 3/10/98
  • WASBMT Treatment of severe Wiskott-Aldrich syndrome by allogeneic BMT using mismatched-related or phenotypically similar unrelated donors; 5/27/98-2001.
  • WASMSD Treatment of severe Wiskott-Aldrich syndrome by allogeneic BMT using matched sibling donors; open 5/27/98
  • POCPT Phase I study of IV irinotecan (CPT11) given orally in pediatric patients with refractory solid tumors; opened 8/6/98
  • RET4 Treatment for extrachordoidal or metastatic retinoblastoma; opened 11/03/97
  • NB-97 Therapy for children with advanced stage high-risk neuroblastoma; 10/1/97-4/2001.
  • HIRISA2 Intensified vincristine, ifosfamide, doxorubicin, cyclophosphamide and etoposide for children with high-risk sarcoma; Opened 9/20/97.
  • CB9701 Phase II multicenter, open label dose escalation clinical trial examining multi IV infusions of 4 doses ABX-CBL patients with steroid resistant GVHD; open 1/22/99
  • CB9702 An open label clinical trial for patients with acute GVHD who have previous exposure to ABX-CBL; open 4/30/98
  • CPSAAT Matched-unrelated donor bone marrow transplantation for recipients with plastic anemia – clinical management plan; open 9/23/97-5/2001.
  • GANGL2 Allogeneic bone marrow transplantation for children with severe form of GM1 gangliosidosis or galactosialidosis; open 1/18/99-5/2001.
  • SCALLO Allogeneic bone marrow transplant from HLA/MLC genotype identified donors for patients with HR hemoglobin SS, SC, & SB thalassemia disease; opened 12/29/92
  • STEM 98 Collection, storage & distribution of hematopoietic cells for research purposes; open 2/24/98
  • NB8814 Pilot Study of Chemotherapy and Recombinant Human Granulocyte Stimulating Factor in Children with Advanced Neuroblastoma; open 7/25/89 – close 2/4/92
  • ICE Phase I-II Trial of Pharmacokinetically Determined Escalating Doses of Carboplatin (CBDCA) combined with Ifosfamide and Etoposide in Patients with Newly Diagnosed Advanced-Stage Malignant Solid Tumor or any Recurrent Malignant Solid Tumor; open 2/6/90 – closed 2/9/93
  • VIP Phase I/II Study of Oral VP-16 in Patient with Malignant Solid Tumors; open 5/28/91 – close 1/11/94
  • LYSUL Phase I Study of Sulofenur (LY 186641) in Pediatric Patients with Drug Resistant Malignant Solid Tumors; open 6/26/91 – close 8/9/94
  • ICE-IL-1 (protocol 9107), Phase I/II Trial of Subcutaneous rhu-IL-1a Administered Pre-Chemotherapy in Pediatric Patients with Malignant Solid Tumors; open 6/11/91 – close 7/13/93
  • NB 91 A Pilot Study of Intensified Chemotherapy with Recombinant Human Granulocyte Colony Stimulating Factor (rG-CSF) and a-Erythropoietin (EPO) Followed by Interferon-a for Children with Advanced Neuroblastoma; open 1/14/92
  • RMS VII Phase II Study of High Dose Methotrexate Administered as Up-front Window Therapy in Patients with Newly Diagnosed Advanced Rhabdomyosarcoma; open 1/26/93 – close 4/23/96
  • PANG Use of Marker Genes to Investigate the Mechanism of Rel & the Effect of Bone Marrow Purging in Autologous Transplantation for Stage D Neuroblastoma; open 9/7/93
  • PIXY Phase I/II Trial of Subcutaneous PIXY 321 in Pediatric Patients with Malignant Solid Tumors Administration After Ifos/Carbo/Etoposide ICE Chemo; open 1/19/93 – close 9/16/94
  • AE-6 Evaluation of Single-Dose I.V. Ondansetron for the Prevention of Nausea and Vomiting Induced by Emetogenic Cancer Chemotherapy Regimens; open 5/14/91 – closed 6/2/92
  • RMS VI Phase I/II Study of Recombinant Human GM-CSF After Vincristine, Actinomycin-D, and Ifosfamide (VAI) Chemotherapy for Treatment of Children with Newly Diagnosed Advanced Stage Rhabdomysarcoma (RMS); open 5/15/91 – closed 6/23/92
  • RMS V Phase II/III Protocol for the Treatment of Previously Untreated High Risk Childhood Rhabdomyosarcoma; open 8/12/86 – closed 7/3/91
  • RDOG(4)6880 Radiological Diagnostic Oncology Group, “The Detection and Staging of Pediatric Solid Tumors; A Multicenter Study Sponsored by the National Cancer Institute”; open 11/93
  • OLALIA Open Label, Non-Comparative Study of ABLC in the Treatment of Definite or Probable Invasive Aspergillosis; open 3/28/95
  • RALF Randomized Study of ABLE vs. Amphotericin B Desoxycholate in the Empiric Treatment for Fungal Infection in Neutropenic Patients; open 3/28/95
  • ETNA Administration of neomycin resistance gene marker; open 8/3/93
  • PAMYLA Assessment of the efficacy of purging by using gene marked autologous marrow transplant for children with AML in remission; open 8/5/93
  • DRECK Reconstitution of Untreated & Cytokine Expanded CD34+ Selected Marrow Cells in Patients Undergoing Autologous BMT; open 6/10/95
  • CBOM A Comparative Evaluation of the Utility of Hematopoietic Progenitor Cells Derived from Peripheral Blood vs. Bone Marrow; open 7/11/95
  • AMATOR The Adoptive Transfer of Minor Histocompatibility Antigen Specific Cytotoxic Lymph. for Treatment of Relapsed Leukemia; open 7/17/95

Principal Investigator:

  • STBMT1 Tumor purging of autologous stem cell grafts in children with high-risk solid tumors: transplantation of retrovirally marked stem cell grafts purified by CD34+ antibody selection and high-speed cell sorting; open 6/99
  • CYTOP Dose intensive cyclophosphamide & topotecan with stem cell support for children with high-risk solid malignancies; open 11/2/98
  • CYCHAL Phase I study of chemokine & cytokine gene modified allogeneic NB cells for treatment of relapse/refractory NB using retroviral vectors; 8/26/98-3/14/2000.
  • CYCHE Phase I study of chemokine & cytokine gene-modified autologous NB cells for treatment of relapse/refractory NB using adenoviral vectors; 8/26/98-1/6/2000.
  • CYGENE Phase I Study of Cytokine-Gene Modified Autologous Neuroblastoma Cells for Treatment of Relapsed/Refractory Neuroblastoma; open 8/20/92
  • CANA Phase I Study of Cytokine Gene Modified Autologous Neuroblastoma Cells for Treatment of Relapsed/Refractory Neuroblastoma/Adeno Vector; open 10/3/95-1/6/2000.
  • BEAL1 Allogeneic bone marrow transplantation for patients with hematologic malignancies and HLA-identical sibling donors; opened 10/16/95.
  • ILPO Interleukin-2 post allogeneic bone marrow transplantation for patients with high risk hematologic malignancies and HLA-Identical sibling donors; opened 9/15/95-9/1999.
  • CPMSMD Combination of CD6 and CD8 monoclonal antibodies for in vitro T-cell depletion of donor marrow; 7/16/97-5/2001.
  • PEPSCI A pilot trial of pentoxifylline and cytoxan to prevent GVHD and reduce post-BMT toxicity in recipients of MHC identical sibling allografts; closed 1/16/96
  • HYDROX Hydroxyurea for Children with Recurrent Neuroblastoma; open 12/18/93
  • MIBG Scanning in Neuroblastoma; open 1/14/86 – closed 11/19/91
  • POTOPO Phase I Study of Oral Topotecan in Children and Adolescents with Relapsed Solid Tumors; open 11/30/94
  • VP16CI VP16 Continuous Infusion: A Phase I & II Study in Solid Tumors; open 7/9/85 – close 10/16/90
  • NEBREL A Phase I Trial of High-Dose Carboplatin and Etoposide with Autologous Marrow Support for Treatment of Relapse/Refractory Neuroblastoma Without Apparent Bone Marrow Involvement: Use of Marker Genes to Investigate the Biology of Marrow Reconstitution and the Mechanism of Relapse; open 10/15/91 – close 3/12/96
  • NEBREM A Phase I Trial of High-Dose Carboplatin and Etoposide with Autologous Marrow Support for Treatment of Stage D Neuroblastoma in First Remission; open 10/15/91- close 3/12/96

SJCRH INSTITUTIONAL COMMITTEES:

  • 1987-91 Quality Assurance Committee
  • 1988-01 Metabolic Support Service Committee
  • 1992-93 Clinical Privileges Committee
  • 1991-97 Metabolic and Infusion Support Service Committee, Chairperson
  • 1994-97 Pharmacy and Therapeutics Committee
  • 1995-01 Pain Committee
  • 1998-00 Faculty Appointment and Promotion Committee
  • 1999-01 Medical Executive Committee

HONORS AND AWARDS

  • American Society of Clinical Oncology Young Investigator Award – May, 1986

REVIEWER

  • Journal of Clinical OncologyCancer
  • American Journal of Pediatric Hematology/Oncology
    Bone Marrow Transplantation

PUBLICATIONS

Original Articles:

  • Bowman LC, Houghton JA, Houghton PJ. GTP influences the binding of vincristine in human tumor cytosols. Biochem Biophys Res Commun 135:695-700, 1986.
  • Houghton PJ, Houghton JA, Bowman LC, Hazelton BJ. Therapeutic selectivity of vinca alkaloids: A role for guanosine 5′-triphosphate? Anticancer Drug Design 2:165-179, 1987.
  • Bowman LC, Houghton JA, Houghton PJ. Formation and stability of vincristine-tubulin complex in kidney cytosols. The role of GTP and GTP hydrolysis. Biochem Pharmacol 37:1251-1257, 1988.
  • Marina NM, Etcubanas E, Parham D, Bowman LC, Green A. Peripheral primitive neuroectodermal tumor (peripheral neuroepithelioma) in children: A review of the St. Jude Experience and controversies in diagnosis and management. Cancer 64:1952-1960, 1989.
  • Pui CH, Hancock ML, Raimondi SC, Head DR, Thompson E, Wilimas J, Kun LE, Bowman LC, Crist WM, Pratt CB. Myeloid neoplasia in children treated for solid tumors. Lancet 336:417-421, 1990.
  • Bowman LC, Houghton JA, Houghton PJ. Influence of guanine nucleotides on vincristine binding in tumor cytosols and purified tubulin: Evidence for an inhibitor of vincristine binding. J Cell Physiol 144:376-382, 1990.
  • Hanna SL, Magill HL, Parham DM, Bowman LC, Fletcher BD. Childhood chondrosarcoma: MR imaging with gadolinium-DTPA. Magn Reson Imaging 8(5):669-672, 1990.
  • Bowman LC, Santana VM, Green AA, Furman WL, Hancock ML, Crist WM. Staging systems in neuroblastoma: Which is best? (Letter) J Clin Oncol 9:189-191, 1991.
  • Furman WL, Fairclough DL, Huhn RD, Pratt CB, Stute N, Petros WP, Evans WE, Bowman LC, Douglass EC, Santana VM, Meyer WH, Crist WM. Therapeutic effects and pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor in childhood cancer patients receiving myelosuppressive chemotherapy. J Clin Oncol 9:1022-1028, 1991.
  • Bowman LC, Hancock ML, Santana VM, Hayes FA, Kun L, Parham DM, Furman WL, Rao BN, Green AA, Crist WM. Impact of intensified therapy on clinical outcome in infants and children with neuroblastoma: The St. Jude Children’s Research Hospital experience, 1962 to J Clin Oncol 9:1599-1608, 1991.
  • Look AT, Hayes FA, Shuster JJ, Douglass EC, Castleberry RP, Bowman LC, Smith EI, Brodeur GM. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma. J Clin Oncol 9:581-591, 1991.
  • Kellie SJ, Hayes FA, Bowman L, Kovnar EH, Langston J, Jenkins JJ III, Pao WJ, Ducos R, Green AA. Primary extracranial neuroblastoma with central nervous system metastases characterization by clinicopathologic findings and neuroimaging. Cancer 68:1999-2006, 1991.
  • Lobe TE, Vera SR, Bowman LC, Fontanesi J, Britt LG, Gaber AO. Hepaticopancreaticogastroduodenectomy with Transplantation for Metastatic Islet Cell Carcinoma in Childhood. J Ped Surg 27(2):227-229, 1992.
  • Philippe, PG, Rao BN, Rogers DA, Fontanesi J, Bowman L, Parham D, Shapiro D, Lobe TE, Fleming I. Sarcomas of the Flexor Fossae in Children: Is Amputation Necessary? J Ped Surg 27(8):964-967, 1992.
  • Santana VM, Schell MJ, Williams R, Bowman LC, Thompson EI, Brenner MK, Mirro J. Escalating Sequential High-Dose Carboplatin and Etoposide with Autologous Marrow Support in Children with Relapsed Solid Tumors. Bone Marrow Transplantation 10:457-462, 1992.
  • Marina, NM, Rodman R, Shema SJ, Bowman LC, Douglass E, Furman W, Santana VM, Hudson M, Wilimas J, Meyer W, Madden T, Pratt C. Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with relapsed solid tumors, J Clin Oncol 11(3): 554-560, 1993.
  • Gururangan S, Bowman LC, Parham DM, Wilimas JA, Rao B, Pratt CB, Douglass EC. Primary extracranial rhabdoid tumors: Clinicopathologic features, and response to ifosfamide. Cancer 71(8): 2653-2659, 1993.
  • Rodgers DA, Rao BN, Bowman LC, Marina NM, Fleming ID, Schropp KP, Lobe TE. Primary malignancy of the salivary gland in children. J. Ped. Surg, 29(1):44-47, 1994.
  • Pappo AS, Etcubanas E, Santana VM, Rao BN, Kun L, Fontanesi J, Roberson PK, Bowman LC, Crist WM, Shapiro DN. A phase II trial of ifosfamide in previously untreated children and adolescents with unresectable rhabdomyosarcoma. Cancer 71(6): 2119-2125, 1993.
  • Pratt CB, Meyer WH, Douglass E, Bowman L, Wilimas J, Ochs J, Marina N, Thompson E, Avery L. Phase I study of ifosfamide with mesna given daily for 3 consecutive days to children with malignant solid tumors. Cancer 71:3661-3665, 1993.
  • Sandoval C, Pui C-H, Bowman L, Hurwitz C, Raimondi S, Behm F, Head D. Secondary Acute Myeloid Leukemia in Children Previously Treated with Alkylating Agents, Intercalating Topoisomerase II Inhibitors and Irradiation. J Clin Oncol 11(6):1039-1045, 1993.
  • Brown TF*, Bowman LC, Hellerstein S., Warady BA. Neuroblastoma following renal transplant. Pediatr Nephrol 7(4):446-448, 1993.
  • Brenner M, Santana V, Bowman L, Furman W, Heslop H, Krance R, Mahmoud H, Boyett J, Moss T, Moen RC, Mills B. Use of marker genes to investigate the mechanism of relapse and the effect of bone marrow purging in autologous transplantation for Stage D neuroblastoma. Human Gene Ther 4:809-820, 1993.
  • Pratt CB, Stewart C, Santana VM, Bowman L, Furman W, Ochs J, Marina N, Kuttesch JF, Heideman R, Sandlund JT, Avery L, Meyer WH. Phase I study of topotecan for pediatric patients with malignant solid tumors. J Clin Oncol 12(3):539-543, 1994.
  • Marina NM, Rodman JH, Murry DJ, Shema SJ, Bowman LC, Jones DP, Furman W, Meyer WH, Pratt CB. Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in treatment of newly diagnosed pediatric solid tumors. J Natl Cancer Inst 86(7):544-8, 1994.
  • Mathew P, Ribiero RC, Sonnichsen D, Relling M, Pratt C, Mahmoud H, Bowman L, Meyer W, Avery L, Crist W. Phase I study of oral etoposide in children with refractory solid tumors. J Clin Oncol 12:1452-1457, 1994.
  • Winer-Muram H, Bowman L, Parham D. Intrathoracic desmoid tumor: CT and MRI appearance. Southern Medical Journal, 87(10):1007-1009, 1994.
  • Fontanesi J, Rao BN, Fleming ID, Bowman LC, Pratt CB, Furman WL, et al. Pediatric brachytherapy. The St. Jude Children’s Research Hospital experience. Cancer; 74(2):733-739, 1994.
  • Rill R, Santana VM, Roberts M, Neilson T, Bowman L, Krance RA, Heslop HE, Moen RC, Ihle JN, Brenner MK. Direct demonstration that autologous bone marrow transplantation for solid tumors can return in a multiplicity of tumorigenic cells. Blood 84:380-383, 1994.
  • Relling MV, McLeod HL, Bowman LC, Santana VM. Etoposide pharmacokinetics and pharmacodynamics after acute and chronic exposure to cisplatin. Clin Pharmacol Ther 56(5):503-511, 1994.
  • Pratt CB, Meyer WH, Howlett N, Douglass EC, Bowman LC, Poe D, Mounce K, Kun LE, Houghton JA. Phase II study of 5-Fluorouracil/Leucovorin for pediatric patients with malignant solid tumors. Cancer 74(9):2593-2598, 1994.
  • Marina NM, Shema SJ, Bowman LC, Rodman J, Douglass EC, Furman WL, Pappo A, Santana VM, Hudson M, Meyer WH, Pratt CB. Failure of GM-CSF to reduce febrile neutropenia in children with recurrent solid tumors treated with ICE chemotherapy. Med Ped Oncol 23(4):328-334, 1994.
  • Kaste SC, Hopkins KP, Bowman LC. Dental abnormalities in long-term survivors of head and neck rhabdomyosarcoma. Med Ped Oncol 25(2):96-101, 1995.
  • Kanwar VS, Gajjar A, Ribeiro, RC, Bowman L, Parham DM, Jenkins JJ. Unusual cutaneous toxicity following treatment with dactinomycin: A report of two cases. Med Pediatr Oncol 24:329-333, 1995.
  • Regine WF, Fontanesi J, Kumar P, Zeitzer K, Greenwald C, Bowman L, Shapiro D, Rao B, Kun L. A Phase II trial evaluating selective use of altered radiation dose and fractionation in patients with unresectable rhabdomyosarcoma. Int J Rad Oncol Biol Phys 31(4):799-805, 1995.
  • Regine WF, Fontanesi J, Kumar P, Ayers D, Bowman LC, Pappo AS, Coffey DH, Avery L, Rao BN, Kun LE. Local tumor control in rhabdomyosarcoma following low-dose irradiation: Comparison of group II and select group III patients. Int J Rad Oncol Biol Phys 31(3):485-491, 1995.
  • Cohn SL, Look AT, Joshi VJ, Holbrook T, Salwen S, Chagnovich D, Chesler L, Rowe ST, Valentine MB, Komuro H, Castleberry RP, Bowman LC, Rao PV, Seeger RC, Brodeur GM. Lack of correlation of N-myc gene amplification with prognosis in localized neuroblastoma: a Pediatric Oncology Group study. Cancer Research 55(4):721-726.
  • Pratt CB, Bowman LC, Marina N, Pappo A, Avery L, Luo X, Meyer WH. A phase I study of sulofenur in refractory pediatric malignant solid tumors. Investigational New Drugs 13(1):63-66, 1995.
  • de Cou JM, Bowman LC, Rao BN, Santana VM, Furman WL, Luo X, Lobe TE, Kumar M. Infants with metastatic neuroblastoma have improved survival with resection of the primary tumor. J Ped Surg 30(7):937-940, 1995.
  • de Cou JM, Rao BN, Parham DM, Lobe TE, Bowman L, Pappo AS, Fontanesi J. Malignant peripheral nerve sheath tumors: The St. Jude Children’s Research Hospital Experience. Ann of Surg Oncol 2(6):524-529, 1995.
  • Mathew P, Bowman L, Williams R, Jones D, Rao B, Schropp K, Warren B, Klyce MK, Whitington G, Hudson M. Complications and effectiveness of gastrostomy feedings in pediatric cancer patients. Am J Pediatr Hem Onc 18(1):81-85, 1996.
  • Heslop HE, Brenner MK, Krance RA, Bowman LC, Heideman R, Richardson S, Alexander B, Srivastava DK, Boyett J. Use of double marking with retroviral vectors to determine rate of reconstitution of untreated and cytokine expanded CD34+ marrow cells in patients undergoing autologous bone marrow transplantation. Human Gene Therapy 7:655-667, 1996.
  • Pappo AS, Parham DM, Cain A, Luo X, Bowman LC, Furman WL, Rao BN, Pratt CB. Alveolar soft part sarcoma in children and adolescents: Clinical features and outcome of 11 patients. Med Ped Oncol 26:81-84, 1996.
  • Kuttesch JF, Parham DM, Luo X, Meyer WH, Bowman L, Shapiro DN, Pappo AS, Crist WM, Beck WT, Houghton PJ. P-glycoprotein expression at diagnosis may not be a primary mechanism of therapeutic failure in childhood rhabdomyosarcoma. J Clin Oncol 14:886-900, 1996.
  • Gross E. Rao BN, Pappo A, Bowman L, Shearer P, Kaste S, Greenwald C, Michalkiewicz E, Pratt C. Epithelioid sarcoma in children. J Ped Surg 31:1663-1665, 1996.
  • O’Rielly R, Cheung NK, Bowman L, Castle V, Hoffer F, Kapoor N, Kletzel M, Lindsley K, Shamberger R, Tubergen D. NCCN pediatric neuroblastoma practice guidelines. The National comprehensive Cancer Network. Oncology 10:1813-1822, 1996.
  • Bowman LC, Castleberry RP, Cantor A, Joshi VV, Cohn SL, Smith EI, Yu A, Brodeur GM, Hayes FA, Look AT: Genetic staging of unresectable or metastatic neuroblastoma in infants: A Pediatric Oncology Group Study. J Natl Cancer Inst 89:373-80, 1997.
  • Gross E, Rao BN, Bowman L, Michalkiewicz E, Pappo A, Santana V, Kaste S, Greenwald C, Pratt C. Outcome of treatment for pediatric sarcoma of the foot: A retrospective review over a 20-year period. J Ped Surg 32:1181-1184, 1997.
  • Pappo AS, Bowman LC, Furman WL, Rao BN, Kun LE, Jenkins JJ, Crom WR, Luo X, Kaste SC, Avery L, Meyer WH, Shapiro DN, and Crist WM. A phase II trial of high-dose methotrexate in previously untreated children and adolescents with high-risk unresectable or metastatic rhabdomyosarcoma. J Ped Hematol Oncol 19: 438-442, 1997.
  • Hongeng S, Krance RA, Bowman LC, Srivastava DK, Cunningham JM, Horwitz, EM, Brenner MK, Heslop HE. Essentially identical outcomes of transplantation with HLA-matched sibling and unrelated donor bone marrow in children with leukemia. Lancet 350:767-770, 1997
  • Michalkiewicz EL, Rao BN, Gross E, Luo X, Bowman LC, Pappo AS, Kaste SC, Hudson MM, Greenwald CA, Jenkins JJ, Pratt CB. Complications of pelvic exenteration in children who have genitourinary rhabdomyosarcoma. J Pediatr Surg 32:1277-1282, 1997.
  • Belgaumi AF, Kauffman WM, Jenkins JJ, Cordoba J, Bowman LC, Santana VM, Furman WL. Blindness in children with neuroblastoma. Cancer 80: 1997-2004, 1997.
  • Sanders M, Smith K, Klyce K, Bowman L. Megestrol acetate usage in children with cancer or AIDS. Nutr Clin Prac 12:94, 1997.
  • Kaste SC, Hopkins KP, Bowman LC, Santana VM. Dental abnormalities in children treated for neuroblastoma. Med Ped Oncol 30:22-27, 1998.
  • Hinds PS, Oakes L, Quargnenti A, Furman W, Sandlund JT, Bowman L, Olson MS, Heideman R. Challenges and issues in conducting descriptive decision-making studies in pediatric oncology: A tale of two studies. J Ped Oncol Nurs 15:10-17, 1998
  • Thompson J, Pratt CP, Stewart CF, Avery L, Bowman L, Zamboni W, Pappo A. Phase I study of DMP840 in Pediatric patients with refractory solid tumors. Investigational New Drugs 16:45-49, 1998.
  • Rooney CM, Smith CA, Ng CY, Loftin SK, Sixbey JW, Gan Y, Srivastava DK, Bowman LC, Krance RA, Brenner MK, Heslop HE. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 92:1549-1555, 1998.
  • Bowman LC, Grossmann M, Rill D, Brown M, Zhong, W-Y, Alexander B, Leimig T, Coustan-Smith E, Campana D, Jenkins J, Woods D, Brenner M. IL-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma. Human Gene Therapy 9:1303-1311, 1998.
  • Katzenstein HM, Bowman LC, Brodeur GM, Thorner PS, Joshi VV, Smith EL, Look AT, Rowe ST, Nash MB, Holbrook T, Alvarado C, Rao PV, Castleberry RP, Cohn SL. The prognostic significance of age, tumor cell ploidy and MYCN oncogene amplification in 110 infants with stage D(S) neuroblastoma: The Pediatric Oncology Group Experience. J Clin Oncol 16:2007-2017, 1998.
  • Bowman LC, Grossman M, Rill D, Brown M, Zhong W, Alexander B, Leimig T, Coustan-Smith E, Campana D, Jenkins J, Woods D, Kitchingman G, Vanin E, Brenner M. Antitumor immune responses induced by IL2 gene-modified tumor cells in children with advanced neuroblastoma. Blood 92:1941-1949, 1998.
  • Shamberger RC, Smith EI, Joshi VV, Rao PV, Hayes A, Bowman LC, Castleberry RP. The risk of nephrectomy during local control in abdominal neuroblastoma. J Ped Surg 33:161-164, 1998.
  • Walter AW, Shearer PD, Pappo AS, Greenwald CA, Rao BN, Bowman LC, Furman WL, Gajjar A, Jenkins JJ, Pratt CB. A pilot study of vincristine, ifosfamide, and doxorubicin in the treatment of pediatric non-rhabdomyosarcoma soft tissue sarcomas. Med Ped Oncol 30:210-216, 1998.
  • Denys D, Kaste SC, Kun LE, Chaudhary MA, Bowman LC, Robbins KT. The effects of radiation on craniofacial skeletal growth: a quantitative study. International J of Ped Otolaryn 45:7-13, 1998.
  • Gruner BA, DeNapoli TS, Andrews W, Tomlinson G, Bowman L, Weitman SD. Hepatocellular carcinoma n children associated with Gardner syndrome or familial adenomatous polyposis. J Pediatr Hematol Oncol 20:274-278, 1998.
  • Bowman LC, Williams R, Sanders M, Ringwald-Smith K, Baker D, Gajjar A. An algorithm for nutritional support: The experience of the St. Jude Children’s Research Hospital Metabolic and Infusion Support Service. Int J Cancer Supplement 11:76-80, 1998.
  • Wesche WA, Khare V, Rao BN, Bowman LC, Parham DM. Malignant peripheral nerve sheath tumor of bone in children and adolescents. Pediatric and Developmental Pathology 2:159-167, 1999.
  • Hoover M, Bowman LC, Crawford SE, Stack C, Donaldson JS, Grayhack JJ, Tomita T, Cohn SL. Long-term outcome of patients with intraspinal neuroblastoma. Med Ped Oncol 32:353-359, 1999.
  • Furman WL, Stewart CF, Poquette CA, Pratt CB, Santana VM, Zamboni WC, Bowman LC, Ma MK, Hoffer FA, Meyer WH, Pappo AS, Walter AW, Houghton PJ. Direct Translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol 17:1815-1824, 1999.
  • Zamboni WC, Bowman LC, Santana VM, Houghton PJ, Meyer WM, Pratt CB, Heideman RL, Gajjar AJ, Pappo AS, Stewart CF. Interpatient variability in bioavailability and pharmacokinetics of oral topotecan in children with relapsed solid tumors. Cancer Chemotherapy and Pharmacology 43:454-460, 1999.
  • Hale GA, Heslop HE, Bowman LC, Rochester RA, Pui C-H, Brenner MK, Krance RA. Bone marrow transplantation for therapy-induced acute myeloid leukemia in children with previous lymphoid malignancies. Bone Marrow Transplantation 24:735-739, 1999.
  • Sanders M, Smith K, Gregornik D, Gajjar A, Liu A, Bowman L. Development of a nutrition risk classification for the pediatric cancer patient: Assessment of treatment-induced malnutrition. Nutrition in Clinical Practice 14:45, 1999.
  • Ringwald-Smith K, Williams R, Mackert P, Stricklin L, Sargent T, Bowman L. Comparison of energy estimation equations with measured energy expenditure in obese adolescent patients with cancer. J Am Diet Assoc 99(7):844-848, 1999.
  • Slobod KS, Sandlund JT, Spiegel PH, Haik B, Hurwitz JL, Conley ME, Bowman LC, Benaim E, Jenkins JJ, Stockton R, Gan Y-J, Sixbey JW. Molecular evidence of ocular Epstein-Barr virus infection. Clin Infect Dis 31:184-188, 2000.
  • Phipps S, Dunavant M, Srivastava DK, Bowman L, Mulhern R. Cognitive and academic functioning in survivors of pediatric bone marrow transplantation. J Clin Oncol 18(5): 1004-1011, 2000.
  • Hinds PS, Martinson I, Drew D, Oakes L, Quargnenti A, Furman W, Bowman L, Gilger E, Gattuso J, Yi KH. An International feasibility study on parental decision making in pediatric oncology. Oncol Nurs Forum 27(8): 1233-1243, 2000.
  • Leung W, Hudson MM, Strickland DK, Phipps S, Srivastava DK, Ribeiro RC, Rubnitz JE, Sandlund JT, Kun LE, Bowman LC, Evans WE, Pui C-H. Late effects of treatment in survivors of childhood acute myeloid leukemia. J Clin Oncol 18(18): 3273-3279, 2000.
  • Ringwald-Smith K, Hale G, Williams R, Thompson A, Shochat S, Liu A, Barkley C, Bowman L. Comparison of two different low profile gastrostomy enteral feeding devices in pediatric oncology patients. Nutrition in Clinical Practice 15(4): 189-192, 2000.
  • Leung W, Hudson M, Zhu Y, Rivera GK, Ribeiro RC, Sandlund JT, Bowman LC, Evans WE, Pui CH. Late effects in survivors of infant leukemia. Leukemia 14(7): 1185-1190, 2000.
  • AE Haight, LC Bowman, CYC Ng, EF Vanin, AM Davidoff. Humoral response to vaccination with IL-2 expressing allogeneic neuroblastoma cells. Med Ped Oncol, 35 (6): 712-715, 2000.
  • Steen RG, Helton KJ, Phipps S, Horwitz EM, Benaim E, Thompson S, Bowman LC, Krance R, Wang WC, Cunningham JM. Improved cerebrovascular patency following therapy in patients with sickle cell disease: preliminary results in 4 patients who received HLA-identical hematopoietic stem cell allografts. Ann Neurol 49(2): 222-229, 2000.
  • Leung W, Hudson MM, Strickland DK, Phipps S, Srivastava DK, Ribeiro RC, Rubnitz JE, Sandlund JT, Kun LE, Bowman LC, Razzouk BI, Mathew P, Shearer P, Evans WE, Pui CH. Late Effects of Treatment in Survivors of Childhood Acute Myeloid Leukemia. J Clin Oncol 18:3273-3279, 2000.
  • Mathew P, Rowe ST, Valentine MB, Nash MB, Valentine VA, Bowman LC, Castleberry RP, Cohn SL, Brodeur GM, Look AT. Detection of MYCN gene amplification in neuroblastoma by fluorescence in situ hybridization: A Pediatric Oncology Group Study. Neoplasia 3(2): 105-109, 2001.
  • Hale GA, Tong X, Benaim E, Cunningham JM, Heslop HE, Horwitz EM, Leung W, Rochester RJ, Shearer PD, Srivastava DK, Woodard JP, Bowman LC. Allogeneic bone marrow transplantation in children failing prior autologous bone marrow transplantation. Bone Marrow Transplantation 2001 27:155-162, 2001.
  • Strother D, Ashley D, Kellie SJ, Patel A, Jones-Wallace D, Thompson S, Heideman R, Benaim E, Krance R, Bowman L, Gajjar A. Feasibility of four consecutive high-dose chemotherapy cycles with stem-cell rescue for patients with newly diagnosed medulloblastoma of supratentorial primitive neuroectodermal tumor after craniospinal radiotherapy: Results of a collaborative study. J Clin Oncol 19: 2696-2704, 2001.
  • Athale UD, Razzouk BI, Raimondi SC, Tong X, Behm FG, Head DR, Srivastava DK, Rubnitz JE, Bowman L, Pui CH, Ribeiro RC. Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution’s experience. Blood 97 (12): 3727-3732, 2001.
  • Leung W, Pitts N, Burnette K Cunningham JM, Horwitz EM, Benaim E, Hale G, Woodard P, Pui CH, Bowman LC. Allogeneic bone marrow transplantation for infants with acute leukemia or myelodysplastic syndrome. Bone Marrow Transplant 27(7):717-722, 2001.
  • Woodard P, Wang W, Pitts N, Benaim E, Horwitz E, Cunningham J, Bowman L. Successful unrelated donor bone marrow transplantation for paroxysmal nocturnal hemoglobinuria. Bone Marrow Transplant 27(6):589-592, 2001.
  • Leung WH, Turner V, Richardson SL, Benaim E, Hale G, Horwitz EM, Woodard P, Bowman LC. Effect of HLA class I or class II incompatability in pediatric marrow transplantation from unrelated and related donors. Hum Immunol 62(4):399-407, 2001.
  • Yeoh EJ, Cunningham JM, Yee GC, Houston JA, Richardson SL, Stewart CF, Houghton P, Bowman LC, Gajjar AJ. Topotecan-filgrastim combination is an effective regimen for mobilizing peripheral blood stem cells. Bone Marrow Transplantation 28, 563-571, 2001.
  • Leung W, Turner V, Richardson S, Benaim E, Cunningham J, Hale G, Horwitz E, Shearer P, Woodard P, Bowman L. Effect of HLA Class I or Class II incompatibility in pediatric marrow transplantation from unrelated and related donors. Hum Immunol 62:399-407, 2001.
  • D’Costa S, Slobod KS, Benaim E, Bowman L, Cunnigham J, Holladay M, Howlett N, Srivastava DK, Hurwitz JL. Effect of extended immunosuppressive drug treatment on B cell versus T cell reconstitution in pediatric bone marrow transplant recipients. Bone Marrow Transplant 28:573-80, 2001.
  • Ringwald-Smith KA, Heslop HE, Krance RA, Mackert PW, Hancock ML, Stricklin LM, Bowman LC, Hale GA., Energy expenditure in children undergoing hematopoietic stem cell transplantation Bone Marrow Transplantation 30:125-30, 2002
  • Katzenstein HM, Krailo MD, Malogolowkin, MH, Ortega JA, Liu-Mares W, Douglass EC, Feusner JH, Reynolds M, Quinn JJ, Newman K, Finegold MJ, Haas JE, Sensel MG, Castleberry RP, Bowman LC,. Hepatocellular carcinoma in children and adolescents: results from the Pediatric Oncology Group and the Children’s Cancer Group intergroup study. JCO 20(12):2789-97, 2002
  • Katzenstein HM, London WB, Douglass EC, Reynolds M, Plaschkes J, Finegold MJ, Bowman LC., Treatment of Unresectable and Metastatic Hepatoblastoma: A Pediatric Oncology Group Phase II Study JCO, 20(16):3438-44, 2002
  • Sandlund JT, Bowman L., Heslop HE, Krance R., Mahmoud H., Pui C-H., Hale G., Benaim E., Intensive chemotherapy with hematopoietic stem-cell support for children with recurrent or refactory NHL. Cytotherapy 4 (3):253-258, 2002
  • Wilson MW, Moshfeghi DM, Haik BG, Haight AE, Hill DA, Davidoff AM, Rousseau RE, Bowman LC., Occult Orbital Neuroblastoma Detected after Administration of an Anti-tumor Vaccine, OPRS 1, 2003
  • Haight AE, Kaste SC, Goloubeva O, Xiong XP, Bowman LC., Nephrotoxicity of Iopamidol Administered to Pediatric and young Adult Allogeneic Bone Marrow Transplant Patients, (in-press) Radiology 2003
  • Katzenstein HK, Krailo MD, Malogolowkin MH, Ortega JA, Qu W, Douglass EC, Feusner JH, Reynolds M, Quinn JJ, Newman K, Finegold MJ, Haas JE, Sensel MG, Castleberry RP, Bowman LC. Fibrolamellar Hepatocellular Carcinoma In Children and Adolescents. Cancer, (in-press) 2003
  • Hale GA, Bowman LC, Woodard JP, Cunningham JM, Benaim E, Horwitz EM, Heslop HE, Krance RA, Leung W, Shearer PD, Handgretinger R. Allogeneic Bone Marrow Transplantation For Children With Histiocytic Disorders: Use Of TBI and Omission Of Etoposide In The Conditioning Regimen. Bone Marrow Transplantation (in-press) 2003
  • Bagatell R, Rumcheva P, London WB, Cohn SL, Look AT, Brodeur GM, Frantz C, Joshi V, Thorner P, Rao PV, Castleberry R, Bowman LC. Outcomes of Children with Intermediate-Risk Neuroblastoma After Treatment Stratified by MYCN Status and Tumor Cell Ploidy. JCO 23 (34): 8819-8827, 2005.

Chapters and Reviews:

  • Bowman LC, Santana VM. Neuroblastoma. Rudolph’s Pediatrics 19th Edition.Abraham M. Rudolph (ed.), 24.3.2:1201, 1991.
  • Marina NM, Bowman LC, Pui C-H, Crist WM. Pediatric Solid Tumors. In. Holleb AI, Fink DJ, Murphy GP, (eds.). American Cancer Society Textbook of Clinical Oncology. 2nd Ed. American Cancer Society, Inc. Atlanta, GA, 1992.
  • Bowman LC. Liver Tumors. In, Behrman RE, Kliegman R, Arvin AM, Nelson WE, eds. Nelson Textbook of Pediatrics, 15th Edition. W.B. Saunders, Co., Philadelphia, (Invited).
  • Bowman LC, Riely CA. Management of Pediatric Liver Tumors. In, Cady B, Ravikumar TS, eds. Surgical Oncology Clinics of North America 5(2):451-W.B. Saunders, Co., Philadelphia, 1996.
  • Bowman LC. Cognitive behavioral pain and anxiety interventions in pediatric oncology centers and bone marrow transplant units. J Ped Oncol Nurs 13(1):13-14, (Invited Commentary)
  • Bowman LC. Neuroblastoma. In Steen G, Mirro J, eds. St. Jude Children’s Research Hospital Handbook of Childhood Cancer. Perseus Publishing, 2000.
  • Nienhuis AW, Bowman LC. Future Directions in Cancer Treatment. In Steen G, Mirro J, eds. St. Jude Children’s Research Hospital Handbook of Childhood Cancer. Perseus Publishing, 2000.

Abstracts:

  • Bowman LC, Houghton JA, Houghton PJ. Stability of vincristine-protein complexes is dependent upon GTP. Proc Am Assoc Cancer Res 27:268, 1986.
  • Houghton PJ, Houghton JA, Bowman LC, Dodge R, George S. The influence of drug binding and GTP on the sensitivity of human tumors to vinca alkaloids. Proc. 14th International Cancer Congress 3:853, 1986.
  • Houghton JA, Bowman LC, Hazelton BJ, Houghton PJ. The binding of vincristine (VCR) to tubulin is dependent upon GTP. Proc Am Soc Clin Biol, 1986.
  • Bowman LC, Meyer WH, Douglass EC, Pratt CB. Activity of ifosfamide in metastatic and unresectable osteosarcoma. Proc Annu Meet Am Soc Clin Oncol 6: A844, 1987.
  • Bowman LC, Houghton JA, Houghton PJ. Influence of guanine nucleotides on formation and stability of the vincristine-tubulin complex in tumor cytosols. Proc Am Assoc Cancer Res 28:408, 1987.
  • Bowman LC, Hancock ML, Santana VC, Furman WL, Green AA, Hayes FA. Impact of intensified chemotherapy on clinical outcome in infants and children with neuroblastoma: A single institutional experience, 1962-Pediatr Res 25:148A (Abst. #871), 1989.
  • Bowman LC, Magill HL, Garth KE, Rao BN, Green AA, Hayes FA. 131I Metaiodobenzylguanidine (MIBG) scintigraphy in neuroblastoma: sensitivity and clinicopathologic correlation. Proc Am Assoc Cancer Res, 1989.
  • Kellie SJ, Bowman LC, Langston JW, Pao WJ, Jenkins JJ, Look AT, Ducos R, Green AA, Hayes FA. Primary extracranial neuroblastoma relapsing in the parenchyma of the central nervous system and leptomeninges. Proc Annu Meet Am Assoc Cancer Res 30: A1107, 1989.
  • Bowman LC, Castleberry RP, Altshuler G, Smith EI, Cantor A, Shuster J, Yu A, Look AT, Hayes FA. Therapy based on DNA index (DI) for infants with unresectable and disseminated neuroblastoma (NB): preliminary results of the Pediatric Oncology Group “better risk” study. SIOP XXIInd Meeting, Med Pediatr Oncol, Vol. 18:364 (Abst. #4), 1990.
  • Hayes FA, Bowman LC, Hancock ML, Santana VM, Furman WL, Rao B, Crist WM, Green AA. Clinical outcome with intensified therapy in infants and children with neuroblastoma: St. Jude Experience, 1962-SIOP XXIInd Meeting, Med Pediatr Oncol 18:386 (Abst. #86), 1990.
  • Furman WL, Pratt CB, Fairclough D, Arnold B, Bowman L, Santana V, Meyer W, Crist WM. Phase I-II trial of granulocyte/macrophage colony-stimulating factor after intensive chemotherpay for patients with relapsed neuroblastoma. Med Pediatr Oncol 18(5):383-4, 1990.
  • Pratt CB, Bowman L, Douglass EC, Furman WL, Goren M, Kellie SJ, Kovnar EH, Kun LE, Meyer WH, Ochs JJ. Ifosfamide/Mesna: Alternative phase I schedules and dosages for pediatric malignant solid tumors including brain tumors. Proc Annu Meet Am Soc Clin Oncol 9: A1152, 1990.
  • Furman WL, Pratt CB, Fairclough D, Arnold B, Bowman L, Santana VM, Meyer W, Crist WM. Phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor in children wiht recurrent colid tumors receiving intensive chemotherapy. Proc Annu Meet Am Soc Clin Oncol 9: A1125, 1990.
  • Gururangan S, Bowman L, Rao B, Pratt C, Wilimas J, Parham D, Douglass E. Malignant rhabdoid tumor may respond to regimens containing ifosfamide. Proc Annu Meet Am Soc; Clin Oncol 11: A1298, 1992.
  • Marina N, Madden T, Rodman J, Douglass E, Furman W, Bowman L, Hudson M, Meyer W, Pratt C. Pediatric Phase I-II trail of targeted dose escalation for carboplatin in combination with ifosfamide/etoposide. Proc Annu Meet AM Soc Clin Oncol 10: A1107, 1991.
  • Kellie SJ, Bowman LC, Langston JW, Pao WJ, Jenkins JJ, Look AT, Ducos R, Green AA, Hayes FA. Primary extracranial neuroblastoma with CNS metastases. Characterization by clinicopathologic and neuroimaging features. Med Pediatr Oncol 19(5): 358, 1991.
  • Bowman LC, Castleberry R, Altshuler G, Joshi V, Smith E, Cantor A, Shuster J, Yu A, Look A, Brodeur G, Hayes F. Therapy based on DNA index for infants with unresectable and disseminated neuroblastoma: The Pediatric Oncology Group “Better Risk” Study. Proc Ann Meeting Amer Soc Clin Oncol 11:A1257, 1992.
  • Marina N, Rodman J, Shema S, Madden T, Douglass E, Furman W, Bowman L, Meyer W, Pratt C. Carboplatin, ifosfamide, etoposide, combination chemotherapy (ICE) for recurrent solid tumors. Proc Annu Meet Am Soc Clin Oncol 11: A1258, 1992.
  • McLeod HL, Santana VM, Bowman LC, Furman WL, Relling MV. Etoposide pharmacokinetics are influenced by acute but not chronic cisplatin exposure. Proc Annu Meet Am Assoc Cancer Res 33: A3174, 1992.
  • Fairclough DL, Furman WL, Bowman LC, Santana VM, Meyer WH. Received dose intensity and outcome in disseminated neuroblastoma over 1 yr of age. Proc Annu Meet Am Soc Clin Oncol 11: A1271, 1992.
  • Fontanesi J, Bowman LC, Hancock M, Furman WL, Santana V, Meyer WH, Kun L. Impact of irradiation on local control in advanced neuroblastoma. Proc Amer Assoc Can Res 33:A1538, 1992.
  • Mathew P, Relling M Sonnichsen D, Luo X, Bowman L, Pratt C, Crist W, Ribiero R. Phase I study of daily oral etoposide in children with refractory solid tumors. Proc Annu Meet Am Soc Clin Oncol 12: A1455, 1993.
  • Marina N, Shema S, Rodman J, Bowman L, Furman W, Pappo A, Meyer W, Pratt C. Ifosfamide, carboplatin and etoposide combined with human granulocyte-macrophage stimulating factor in children with recurrent solid tumors. Proc Annu Meet Am Soc Clin Oncol 12: A1453, 1993.
  • Marina N, Murry D, Rodman J, Shema S, Bowman L, Furman W, Meyer W, Pratt C. Phase I study of escalating targeted doses of carboplatin combined with ifosfamide and etoposide in children with untreated malignancies. Proc Annu Meet Am Soc Clin Oncol 12: A1429, 1993.
  • Furman W, Fairclough D, Garrison L, Marina N, Avery L, Pratt C, Bowman L, Santana V, Bleyer A, Rodman J. A phase I/II trial of sc inerleukin-1 alpha administered prechemotherapy in pediatric patients with malignant solid tumors. Proc Annu Meet Am Soc Clin Oncol 12: A1405, 1993.
  • Pratt C, Stewart C, Santana V, Bowman L, Meyer W, Sandlund J, Furman W, Heideman R, Kuttesch J. Phase I study of topotecan for pediatric patients with drug-resistant solid tumors. Proc Annu Meet Am Soc Clin Oncol 12: A1403, 1993.
  • Regine WF, Fontanesi J, Bowman L, Pappo A, Coffey D, Kun LE. Evaluation of local control with selective use of low-dose irradiation following induction/preoperative chemotherapy for locally advanced rhabdomyosarcoma. ASTRO, New Orleans, LA. October 11-15, 1993.
  • Mathew P, Bowman L, Williams R, Jones D, Rao B, Scropp K, Warren B, Klyce MK, Whitington G, Hudson M. Complications in pediatric cancer patients receiving gastrostomy feedings. Amer Soc Ped Hem-Onc. Chicago, IL. October 6-8, 1994.
  • Santana VM, Bowman L, Furman W, Luo X, Vincent M, Tomita D, Meyer W, Crist W. A Pase I-II trial of human granulocyte colony stimulating factor in children with disseminated neuroblastoma. Proc Annu Meet AM Soc Clin Oncol 13: A1461, 1994.
  • Regine W, Greenwald C, Kumar P, Dombrowski J, Ballas D, Pappo A, Shapiro D, Bowman L, Rao B, Kun L. Use of altered radiation dose and fractionation in patients with unresectable rhabdomyosarcoma based upon disease status following induciton therapy: the St. Jude experience. Proc Annu Meet Am Soc Clin Oncol 13: A1433, 1994.
  • Kuttesch J, Parham D, Luo S, Meyer W, Bowman L, Shapiro D, Pappo A, Crist W, Beck W, houghton P. P-glycoprotein expression at diagnosis is not predictive of worse outcome in pediatric rhabdomyosarcoma. Proc Annu Meet Am Soc Clin Oncol 13: A1409, 1994.
  • Furman WL, Marina N, Luo X, Arnold B, Pratt C, Bowman LC, Santana V, Garrison L, Meyer W. A pediatric phase I/II trail of subcutaneous PIXY321 administered after ifosfamide/carboplatin/etoposide chemotherapy. Proc Annu Meet Am Soc Clin Oncol 13: A1429, 1994.
  • Rao BN, Pappo AC, Bowman L, Pratt CB, Greenwald W, Meyer W. Non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) of the extremity: Prognostic factors influencing survival in children. Joint Meeting EMSOS-AMSTS, Florence, Italy, 1995.
  • Heideman R, Kuttesch J, Stewart C, Meyer W, Bowman L, Furman W, Gajjar A, Avery L, Pratt C. A Phase I trial of a fixed systemic exposure (AUC) of carboplatin with continuous infusion topotecan in pediatric solid tumors. Proc Annu Meet Am Soc Clin Oncol 14:A1430, 1995.
  • Kuttesch J, Stewart C, Meyer W, Bowman L, Furman W, Gajjar A, Avery L, Pratt C. A phase I trial of a fixed systemic exposure (AUC) of carboplatin (CARBO) with continuous infusion (CI) topotecan (TOPO) in pediatric solid tumors. Proc Annu Meet Am Soc Clin Oncol 14:A1409, 1995.
  • Pappo A., Bowman L, Parham D, Rao B, Crist W, Meyer W. Window therapy with high-dose methotrexate (HDMTX) in newly diagnosed advanced stage rhabdomyosarcoma (RMS). Proc Annu Meet Am Soc Clin Oncol 14:A1452, 1995.
  • Bowman L, Crom D, Zacher M, Jones D, Luo X, Hayes FA, Santana V, Furman W, Hudson M, Becker J. Serial echocardiography (ECHO) in children treated in infancy for unresectable or metastatic neuroblastoma (NB) with cyclophosphamide (CTX) and doxorubicin (DOX). Proc Annu Meet Am Soc Clin Oncol 14: A1411, 1995.
  • Khare VK, Bhargava R, Rao BK, Bowman L., Parham MD. Malignant peripheral nerve sheath tumor (MPNST) of bone in children and adolescents. 1995
  • Hopkins K, Kaste SC, Bowman LC. Dental abnormalities in long-term survivors of childhood head and neck rhabdomyosarcoma. 11th Annual Dental Research Symposium, 1996.
  • Rao BN, Lynch M, Meyer W, Pappo A, Bowman L, Kaste SC, Pratt CB, Cremer L, Neel M. Limb salvage for skeletal sarcoma in children and adolescents. SIOP XXVIIIth Meeting Abstract, 1996.
  • Gross E, Rao BN, Pappo A, Bowman LC, Shearer P, Greenwald C, Kaste SC, Pratt CB. Soft tissue sarcomas (STS) of the hand and foot. SIOP XXVIIIth Meeting Abstract, 1996.
  • Michalkiewicz E, Rao BN, Bowman LC, Pappo A, Kaste SC, Hudson MM, Greenwald C, Walter A, Pratt CB. Complications of pelvic exenteration for GU RMS. IPSO Meeting, 1996.
  • Gross E, Rao BN, Pappo AS, Bowman LC, Shearer P, Kaste SC, Walter A, Pratt CB. Epithelioid sarcoma in children. IPSO Meeting, 1996.
  • Greenwald C, Shelton D, Bowman L, Rao B, Lou X, Mulhern R. Quality of life after exenteration for GU rhabdomyosarcoma. 4th International Conference on the long-term complications of treatment of children and adolescents for cancer, 1996.
  • Bowman LC, Stewart CF, Zamboni WC, Crom WR, Luo X, Heideman R, Houghton PJ, Meyer WH, Pratt CB. Toxicity and pharmacodynamics of oral topotecan (POTOPO) in pediatric patients with relapsed solid tumors. Proceedings of ASCO 15:462 (abstr 1453), 1996.
  • Bowman LC, Dilloo D, Rill D, Furman W, Santana VM, Grossman M, and Brenner Mk. Immunization with IL-2 secreting neuroblastoma cells in children with recurrent neuroblastoma. Proceedings of the Am Assoc for Cancer Res 38:630 (abstr 4320), 1997.
  • Sanders M, Smith K, Klyce K, Baker D, Bowman L. Megastrol acetate usage in children with cancer or AIDS. Aspen, 1997.
  • Bowman LC, Grossman M, Rill CR, Brown MP, Zhong W, Alexander B, Leimig T, Coustan-Smith E, Campana D, Jenkins J, Woods D, Kitchingman G, Vanin E, Brenner MK. Anti-tumor immune responses induced by IL-2 gene modified tumor cells in children with advanced neuroblastoma. Blood 90:405a (abstr 1800), 1997.
  • Benaim E, Krance RA, Richardson S, Bowman LC, Srivastava DK, Cunningham JM, Horwitz EM, Brenner MK, Heslop HE. Comparison of outcome of allogeneic transplantation in children with leukemia using unrelated donors or mismatched family member donors. Blood 90: (abstr 466), 1997.
  • Hale GA, Tong X, Benaim E, Cunningham JM, Heslop HE, Horwitz EM, Leung W, Rochester RJ, Shearer PD, Srivastava DK, Woodard JP, Bowman LC. Allogeneic bone marrow transplantation in children failing prior autologous bone marrow transplantation. International Bone Marrow Transplant Registry Meeting, March 2000.
  • Benaim E, Hale GA, Srivastava DK, Cunningham JM, Horwitz EM, Heslop HE, Brenner MK, Krance RA, Bowman LC. Efficacy with minimal toxicity associated with the administration of donor lymphocyte infusions in pediatric bone marrow transplant recipients. Blood (Suppl): A4903, 1999.
  • Woodard P, Benaim E, Cunningham JM, Horwitz EM, Leung W, Shearer P, Hale G, Bowman LC. Characteristics and outcome of graft failure in pediatric recipients of allogeneic stem cell transplants. Blood 94 (Suppl):A1478, 1999.
  • AE Haight, LC Bowman, CYC Ng, EF Vanin, AM Davidoff. Humoral response to vaccination with IL-2 expressing allogeneic neuroblastoma cells. Med Ped Oncol, 35 (6): 712-715, 2000; Advances in Neuroblastoma Research. Philadelphia, 2000.
  • Rousseau RF, Strother D, Rill DR, Mei Z, Smith SC, Popek E, Davidoff AM, Brenner MK and Bowman LC. Lymphotactin and IL-2 gene-modified allogeneic tumor vaccine in patients (PTS) with refractory or relapsed neuroblastoma (NB). Proc Am Assoc Cancer Res 41:633, 2000
  • Haight AE, Woodard P, Srivastava DK, Raimondi SC, Behm FG, Ribeiro RC, Cunningham JM, Benaim E, Horwitz EM, Hale GA, Leung W, Bowman LC. Outcomes ov 44 pediatric MDS and JMML patients treated with allogeneic BMT. Blood 96 (11): 414a, 2000.
  • Leung W, Pitts N, Burnette K, Cunningham J, Horwitz L, Benaim E, Hale G, Woodard P, Pui C-H, Bowman L. A retrospective double-cohort study of allogeneic bone marrow transplantation for infants with acute leukemia or myelodysplastic syndrome. Blood 96(11): 418a, 2000.
  • Haight AE, Davidoff AM, Ng CYC, Vanin EF, Bowman LC. Immunotherapy with IL-2 expressing allogeneic tumor cells after primary therapy for high-risk neuroblastoma: clinical outcomes and generation of both cellular and humoral immune responses. Blood 96(11): 801a, 2000.
  • Rousseau R, Strother D, Hirschmann-Jax C, Rill D, Mei Z, Smith S, Popek E, Diloo D, Davidoff A, Bowman L, Brenner M. Lymphotactin and IL-2 gene-modified allogeneic tumor vaccine in patients with refractory or relapsed neuroblastoma. Blood 96(11): 802a, 2000.
  • Davidoff AM, Corey BL, Rao BN, Hoffer FA, Bowman LC, Furman WL, Santana VM, Shochat SJ Radiographic Assessment of Respectability of Locoregional Disease in Children with High-Risk Neuroblastoma During Neoadjuvant Chemotherapy. Departments of Surgery, Diagnostic Imaging and Hematology/Oncology, St. Jude Children’s Research Hospital, Memphis, Tennessee, USA 38105.
  • Rousseau RF, Haight AE, Hirschmann-Jax C, Yvon ES, Rill DR, Mei Z, Smith SC, Inman S, Cooper K, Alcoser P, Grilley B, Gee A, Popek E, Davidoff A, Bowman LC, Brenner MK, Strother D. Local and Systemic Effects of an Allogeneic Tumor Cell Vaccine Combining Transgenic Human Lymphotactic with Interleukin-2 in Patients with Advanced or Refractory Neuroblastoma. Blood 24, 2002

Invited Presentations:

  • September ’93 American Society of Pediatric Hematology-Oncology Meeting, IL.?Biology and Therapy of Neonatal Neuroblastoma
  • November ’97 International Workshop on Nutritional Morbidity and Childhood Cancer. Puebla, Mexico
  • June ’98 Advances in Neuroblastoma Research, Bathe England
  • November ’99 United Resource Network National Meeting
  • December ’99 National Cancer Institute Clinical Research Series, Bethesda, MD.

Invited Reviewer:

  • January ’99 NIH GCRC Site Visit, University of California at San Diego, San Diego, California
  • March ’99 Office of Orphan Drugs, Rockville, MD.

Biography

Laura C. Bowman, M.D. is a 1981 graduate of Indiana University School of Medicine, Medical University of South Carolina Pediatric Residency (1984), and Fellowship in Pediatric Hematology-Oncology (1987) from St. Jude Children’s Research Hospital. She is board certified in pediatric hematology-oncology, and directed the bone marrow transplant program first at St. Jude and then at Childrens Healthcare of Atlanta/ Egleston. During almost 20 years of caring for children with cancer, she became interested in Eastern Medicine, and collaborated with an acupuncturist in the treatment of patients with difficult problems. She also has experience as a patient receiving acupuncture treatment, and positive results in both arenas prompted her to further pursue her interest. As a graduate of the Helm’s School for Medical Acupuncture, she combines her areas of expertise to provide integral medical, pediatric, and oncology care.

laura-2016